Diagens Issues FY2025 Results Notice; Full Annual Report to be Released by 30 April 2026

Bulletin Express03-31

Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has issued an announcement pursuant to the Note to Rule 13.49(1) of the Hong Kong Listing Rules regarding its financial results for the year ended 31 December 2025.

The company reminds shareholders and potential investors that its unaudited preliminary financial information for FY2025 was included in Appendix IIB of the prospectus dated 20 March 2026, available on both the Hong Kong Stock Exchange (HKEX) and Diagens’ official websites.

Diagens confirmed that the full audited annual report for FY2025 will be published on the same websites and dispatched to shareholders on or before 30 April 2026.

The announcement was authorised by the Board and signed by Chairman and Executive Director Dr. Song Ning on 31 March 2026. The Board currently comprises five executive and non-executive directors and three independent non-executive directors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162374303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162374303","market":"hk","top_or_hot":-1,"title":"Diagens Issues FY2025 Results Notice; Full Annual Report to be Released by 30 April 2026","media":"Bulletin Express","content":"<p>Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has issued an announcement pursuant to the Note to Rule 13.49(1) of the Hong Kong Listing Rules regarding its financial results for the year ended 31 December 2025.</p>\n<p>The company reminds shareholders and potential investors that its unaudited preliminary financial information for FY2025 was included in Appendix IIB of the prospectus dated 20 March 2026, available on both the Hong Kong Stock Exchange (HKEX) and Diagens’ official websites.</p>\n<p>Diagens confirmed that the full audited annual report for FY2025 will be published on the same websites and dispatched to shareholders on or before 30 April 2026.</p>\n<p>The announcement was authorised by the Board and signed by Chairman and Executive Director Dr. Song Ning on 31 March 2026. The Board currently comprises five executive and non-executive directors and three independent non-executive directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Diagens Issues FY2025 Results Notice; Full Annual Report to be Released by 30 April 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiagens Issues FY2025 Results Notice; Full Annual Report to be Released by 30 April 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-31 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has issued an announcement pursuant to the Note to Rule 13.49(1) of the Hong Kong Listing Rules regarding its financial results for the year ended 31 December 2025.</p>\n<p>The company reminds shareholders and potential investors that its unaudited preliminary financial information for FY2025 was included in Appendix IIB of the prospectus dated 20 March 2026, available on both the Hong Kong Stock Exchange (HKEX) and Diagens’ official websites.</p>\n<p>Diagens confirmed that the full audited annual report for FY2025 will be published on the same websites and dispatched to shareholders on or before 30 April 2026.</p>\n<p>The announcement was authorised by the Board and signed by Chairman and Executive Director Dr. Song Ning on 31 March 2026. The Board currently comprises five executive and non-executive directors and three independent non-executive directors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02526","symbol_name":"德适-B","start_time":0,"source_url":"","article_id":"1162374303","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162374303","pubTimestamp":1774958753,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has issued an announcement pursuant to the Note to Rule 13.49(1) of the Hong Kong Listing Rules regarding its financial results for the year ended...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02526":"德适-B"},"translate_title":"Diagens发布2025财年业绩通知；完整年报将于2026年4月30日前发布","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02526":1},"content_text":"Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) has issued an announcement pursuant to the Note to Rule 13.49(1) of the Hong Kong Listing Rules regarding its financial results for the year ended 31 December 2025.\nThe company reminds shareholders and potential investors that its unaudited preliminary financial information for FY2025 was included in Appendix IIB of the prospectus dated 20 March 2026, available on both the Hong Kong Stock Exchange (HKEX) and Diagens’ official websites.\nDiagens confirmed that the full audited annual report for FY2025 will be published on the same websites and dispatched to shareholders on or before 30 April 2026.\nThe announcement was authorised by the Board and signed by Chairman and Executive Director Dr. Song Ning on 31 March 2026. The Board currently comprises five executive and non-executive directors and three independent non-executive directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162374303","isCrawlerRequest":true}